TY - JOUR
T1 - Patología dual en trastornos de ansiedad
T2 - Recomendaciones en el tratamiento farmacológico
AU - Sáiz Martínez, Pilar Alejandra
AU - Sáiz Martínez, Pilar Alejandra
AU - Sáiz Martínez, Pilar Alejandra
AU - Treviño, Luis Jimenez
AU - Treviño, Luis Jimenez
AU - Díaz Mesa, Eva Mª
AU - Díaz Mesa, Eva Mª
AU - García-Portilla González, Mª Paz
AU - García-Portilla González, Mª Paz
AU - García-Portilla González, Mª Paz
AU - González, Pedro Marina
AU - González, Pedro Marina
AU - Al-Halabí, Susana
AU - Al-Halabí, Susana
AU - Szerman, Néstor
AU - Szerman, Néstor
AU - García, Julio Bobes
AU - García, Julio Bobes
AU - García, Julio Bobes
AU - Ruiz, Pedro
N1 - Publisher Copyright:
© 2014 Edita Socidrogalcohol. All rights reserved.
PY - 2014
Y1 - 2014
N2 - Anxiety disorders and substance use disorders are highly comorbid (between 18% and 37%), and such comorbidity complicates treatment and worsens prognosis (including higher suicide risk). There are not many research works on the specific pharmacologic treatment of dual comorbid anxiety disorders. Most authors recommend a simultaneous approach of both, anxiety and substance use, disorders. Research data on pharmacotherapy suggest that psychotropics used in the treatment of anxiety disorders are also effective in dual diagnosis. SSRIs are considered first-line therapy in the treatment of dual anxiety while benzodiacepines should be avoided. New generation antiepileptic have shown efficacy in case series and open label studies in the latest years, thus being a promising treatment option for dual comorbid anxiety disorders, specially pregabalin in generalized anxiety disorder.
AB - Anxiety disorders and substance use disorders are highly comorbid (between 18% and 37%), and such comorbidity complicates treatment and worsens prognosis (including higher suicide risk). There are not many research works on the specific pharmacologic treatment of dual comorbid anxiety disorders. Most authors recommend a simultaneous approach of both, anxiety and substance use, disorders. Research data on pharmacotherapy suggest that psychotropics used in the treatment of anxiety disorders are also effective in dual diagnosis. SSRIs are considered first-line therapy in the treatment of dual anxiety while benzodiacepines should be avoided. New generation antiepileptic have shown efficacy in case series and open label studies in the latest years, thus being a promising treatment option for dual comorbid anxiety disorders, specially pregabalin in generalized anxiety disorder.
KW - Anxiety disorders
KW - Comorbidity
KW - Dual diagnosis
KW - Recommendations
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=84922382863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922382863&partnerID=8YFLogxK
U2 - 10.20882/adicciones.7
DO - 10.20882/adicciones.7
M3 - Article
AN - SCOPUS:84922382863
VL - 26
SP - 254
EP - 274
JO - Adicciones
JF - Adicciones
SN - 0214-4840
IS - 3
M1 - A254
ER -
